Investment Analysts’ Weekly Ratings Updates for Chemours (CC)

Several brokerages have updated their recommendations and price targets on shares of Chemours (NYSE: CC) in the last few weeks:

• 10/20/2026 – Chemours had its price target lowered by Truist Financial Corporation from $24.00 to $20.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Chemours had its “neutral” rating reaffirmed by Mizuho. They now have a $15.00 price target on the stock, down from $18.00.
• 10/13/2026 – Chemours was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $14.00 price target on the stock.
• 10/13/2026 – Chemours was downgraded by Mizuho from “strong-buy” to “hold”.
• 10/12/2026 – Chemours is now covered by Barclays PLC. They set an “equal weight” rating and a $16.00 price target on the stock.
• 10/12/2026 – Chemours was upgraded by Barclays PLC to “hold”.
• 10/9/2026 – Chemours had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $16.00 price target on the stock.
• 10/5/2026 – Chemours had its price target lowered by UBS Group AG from $18.00 to $16.00. They now have a “neutral” rating on the stock.
• 9/30/2026 – Chemours had its price target lowered by Mizuho from $20.00 to $18.00. They now have an “outperform” rating on the stock.
• 9/10/2026 – Chemours was upgraded by Zacks Research from “strong sell” to “hold”.

Chemours Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th were issued a $0.0875 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a yield of 2.7%. Chemours’s dividend payout ratio (DPR) is -18.32%.

Insider Buying and Selling at Chemours

In other Chemours news, CFO Shane Hostetter bought 3,350 shares of the stock in a transaction on Thursday, August 6th. The shares were purchased at an average price of $14.94 per share, with a total value of $50,049.00. Following the acquisition, the chief financial officer directly owned 102,698 shares of the company’s stock, valued at $1,534,308.12. This represents a 3.37% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Denise Dignam purchased 3,378 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the transaction, the chief executive officer owned 339,916 shares in the company, valued at approximately $5,081,744.20. This trade represents a 1.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 8,663 shares of company stock valued at $130,601 in the last 90 days. 0.85% of the stock is currently owned by insiders.

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.